Edinburgh Molecular Imaging Ltd (EM Imaging) is a clinical phase biotechnology company that develops optical molecular imaging technology. It is involved in the discovery and development of small molecules and peptides. The company designs agents to improve the diagnosis and treatment of cancer and lung diseases. Its portfolio of agents includes EMI-137 (CRC Lesion); EMI-200 (Inflammation); EMI-300/350 (Lung Infection); EMI-400 (Lung Fibrosis); EMI-500 (Breast Cancer); and EMI-600 (Single Pulmonary Nodules). SMART Agent optical imaging platform is the foundation technology, which shows the increased fluorescent signal from the optical agents on target engagement in a diseased patient. EM Imaging is headquartered in Edinburgh, Scotland, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Edinburgh Molecular Imaging Ltd
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company